Tetra Bio-Pharma (TBP.T) announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as a comparator in the REBORN1© study. Expanding to three immediate release oral opioids will allow for the acceleration of patient enrolment in the trial.
Latest News
Top 5 Gainers and Losers: KASH.CN, QIMC.CN, TGH.V
Zentek (ZEN.V) took a years long path to figure out its incredible biotech potential
Tesla stock to $100?
Top 5 Gainers and Losers: KASH.CN, DHR.V, BRO.V
Standard Uranium (STND.V) looks to add to Sun Dog’s uranium history
Top 5 Gainers and Losers: SEI.V, LAB.V, NCU.TO